Want to see ADOCY full AI Analyst Report?
Top Page
Adocia
(OTC:ADOCY)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-13.79% Downside)
Action:Reiterated
Date:07/02/26
Overall score is driven primarily by weak financial performance (persistent losses, volatile revenue, ongoing cash burn, and high leverage) and bearish technicals (price below key moving averages with negative MACD). Valuation provides limited support because negative earnings make P/E less actionable and no dividend yield is available.
Positive Factors
Partnership-driven model
A partnership/licensing model shifts commercialization and capex burden to larger pharma partners, enabling Adocia to monetize R&D through upfronts, milestones and royalties. This durable model can scale value capture without large internal commercial investment.
Negative Factors
Persistent net losses
Consistent annual losses and an extreme 2025 net margin reflect a structural inability so far to cover operating costs with revenue. This weak profitability undermines internal reinvestment capacity and necessitates ongoing external funding absent material commercial success.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership-driven model
A partnership/licensing model shifts commercialization and capex burden to larger pharma partners, enabling Adocia to monetize R&D through upfronts, milestones and royalties. This durable model can scale value capture without large internal commercial investment.
Read all positive factors
Adocia (ADOCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$94.14M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth-83.71%
EPS Growth-48.58%
CountryUS
Employees78
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.87
Shares Outstanding20,253,056
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)132.14
Price to Sales (P/S)139.00
P/FCF Ratio-30.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$16.43M
Adocia Business Overview & Revenue Model
Company Description
Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorde...
How the Company Makes Money
Adocia’s business model is primarily partnership- and licensing-driven rather than based on selling marketed drugs directly. The company seeks to monetize its proprietary drug formulation/delivery platforms and its internally developed drug candid...
Adocia Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.42M | 9.32M | 1.95M | 11.45M | 1.44M |
| Gross Profit | 0.00 | 8.20M | 1.26M | 9.61M | 180.00K |
| EBITDA | -17.42M | -6.91M | -17.59M | -3.58M | -19.35M |
| Net Income | -15.94M | -9.32M | -19.23M | -6.90M | -22.75M |
Balance Sheet | |||||
| Total Assets | 28.44M | 27.02M | 24.96M | 30.61M | 30.05M |
| Cash, Cash Equivalents and Short-Term Investments | 17.25M | 7.53M | 12.96M | 17.42M | 15.16M |
| Total Debt | 8.90M | 11.83M | 13.09M | 33.21M | 34.48M |
| Total Liabilities | 26.95M | 30.11M | 31.87M | 43.58M | 43.87M |
| Stockholders Equity | 1.49M | -3.09M | -6.91M | -12.97M | -13.81M |
Cash Flow | |||||
| Free Cash Flow | -6.53M | -15.84M | -5.11M | -15.15M | -19.59M |
| Operating Cash Flow | -6.27M | -15.61M | -4.95M | -14.99M | -19.23M |
| Investing Cash Flow | -264.14K | -258.00K | -138.00K | 21.86M | -361.00K |
| Financing Cash Flow | 15.87M | 10.44M | 629.00K | -4.61M | 6.64M |
Adocia Technical Analysis
Negative
4.64
Price Trends
4.61
Positive
5.03
Negative
6.31
Negative
Market Momentum
<0.01
Positive
47.59
Neutral
4.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADOCY, the sentiment is Negative. The current price of 4.64 is below the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.61, and below the 200-day MA of 6.31, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 4.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADOCY.
Adocia Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $848.95M | -5.47 | -892.07% | ― | ― | -6.14% | |
51 Neutral | $665.99M | -2.45 | -97.77% | ― | ― | 78.59% | |
49 Neutral | $291.16M | -2.33 | -65.08% | ― | -23.36% | 27.52% | |
48 Neutral | $476.11M | -3.79 | -45.45% | ― | 2.33% | 36.86% | |
41 Neutral | $94.14M | -4.25 | -3796.57% | ― | -83.71% | -48.58% |
* General Sector Average
ADOCY
Adocia
4.78
-4.49
-48.44%
ACHV
Achieve Life Sciences
8.48
5.69
203.94%
FATE
Fate Therapeutics
2.45
1.48
152.06%
CBIO
Crescent Biopharma
18.54
4.85
35.43%
CCCC
C4 Therapeutics
3.79
1.12
41.95%
ACTU
Actuate Therapeutics, Inc.
1.30
-7.42
-85.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.